Published in Proc Natl Acad Sci U S A on September 01, 1988
Structure of the reovirus cell-attachment protein: a model for the domain organization of sigma 1. J Virol (1990) 1.71
Infectious subvirion particles of reovirus type 3 Dearing exhibit a loss in infectivity and contain a cleaved sigma 1 protein. J Virol (1995) 1.68
Identification of carbohydrate-binding domains in the attachment proteins of type 1 and type 3 reoviruses. J Virol (2000) 1.64
Characterizing the microenvironment surrounding protein sites. Protein Sci (1995) 1.54
Mutations in type 3 reovirus that determine binding to sialic acid are contained in the fibrous tail domain of viral attachment protein sigma1. J Virol (1997) 1.50
Sequence diversity in S1 genes and S1 translation products of 11 serotype 3 reovirus strains. J Virol (1990) 1.44
Reovirus binding to cell surface sialic acid potentiates virus-induced apoptosis. J Virol (2001) 1.43
Cleavage susceptibility of reovirus attachment protein sigma1 during proteolytic disassembly of virions is determined by a sequence polymorphism in the sigma1 neck. J Virol (1998) 1.22
Vertical transmission of human immunodeficiency virus (HIV) infection. Reactivity of maternal sera with glycoprotein 120 and 41 peptides from HIV type 1. J Clin Invest (1992) 1.20
Molecular mimicry of hepatitis B surface antigen by an anti-idiotype-derived synthetic peptide. Proc Natl Acad Sci U S A (1992) 1.16
Binding of type 3 reovirus by a domain of the sigma 1 protein important for hemagglutination leads to infection of murine erythroleukemia cells. J Clin Invest (1992) 1.12
Peptide mimicry of the meningococcal group C capsular polysaccharide. Proc Natl Acad Sci U S A (1995) 1.03
Development of biologically active peptides based on antibody structure. Proc Natl Acad Sci U S A (1989) 1.03
Persistent reovirus infections of L cells select mutations in viral attachment protein sigma1 that alter oligomer stability. J Virol (1996) 0.99
Association of the reovirus S1 gene with serotype 3-induced biliary atresia in mice. J Virol (1994) 0.96
The promise of the anti-idiotype concept. Front Oncol (2012) 0.85
The Development of Rapastinel (Formerly GLYX-13); A Rapid Acting and Long Lasting Antidepressant. Curr Neuropharmacol (2017) 0.78
Anti-reovirus receptor antibody accelerates expression of the optic nerve oligodendrocyte developmental program. Proc Natl Acad Sci U S A (1991) 0.77
Ligand binding to the cell surface receptor for reovirus type 3 stimulates galactocerebroside expression by developing oligodendrocytes. Proc Natl Acad Sci U S A (1990) 0.77
Foot-and-mouth disease virus-neutralizing antibodies induced in mice by anti-idiotypic antibodies. Immunology (1989) 0.76
Structure based antibody-like peptidomimetics. Pharmaceuticals (Basel) (2012) 0.76
Proline-rich tandem repeats of antibody complementarity-determining regions bind and neutralize human immunodeficiency virus type 1 particles. J Virol (1996) 0.75
Anti-peptide monoclonal antibody imaging of a common binding domain involved in muscle regulation. Protein Sci (1995) 0.75
THE PREPARATION OF I-131-LABELLED HUMAN GROWTH HORMONE OF HIGH SPECIFIC RADIOACTIVITY. Biochem J (1963) 61.56
Prediction of protein conformation. Biochemistry (1974) 20.51
Evidence for functional domains on the reovirus type 3 hemagglutinin. Virology (1982) 2.55
Identification of attenuating mutations on the reovirus type 3 S1 double-stranded RNA segment with a rapid sequencing technique. J Virol (1986) 2.15
Attenuated reovirus type 3 strains generated by selection of haemagglutinin antigenic variants. Nature (1982) 2.11
Sequence of reovirus haemagglutinin predicts a coiled-coil structure. Nature (1985) 1.95
Isolation and biochemical characterization of the mammalian reovirus type 3 cell-surface receptor. Proc Natl Acad Sci U S A (1985) 1.70
Cell receptors for the mammalian reovirus. I. Syngeneic monoclonal anti-idiotypic antibody identifies a cell surface receptor for reovirus. J Immunol (1983) 1.46
Nucleic acid sequence of an internal image-bearing monoclonal anti-idiotype and its comparison to the sequence of the external antigen. Proc Natl Acad Sci U S A (1986) 1.43
Binding of 125I-labeled reovirus to cell surface receptors. Virology (1984) 1.26
Cell receptors for the mammalian reovirus. II. Monoclonal anti-idiotypic antibody blocks viral binding to cells. J Immunol (1983) 1.26
Syngeneic monoclonal internal image anti-idiotopes as prophylactic vaccines. J Immunol (1986) 1.26
Topological analysis of the reovirus type 3 hemagglutinin. Virology (1983) 1.20
Towards a unified theory of immunoglobulin structure-function relations. Immunol Rev (1986) 1.00
Perspectives on antigenicity and idiotypy. Int Rev Immunol (1987) 0.82
The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen. Nature (1985) 6.23
Molecular model of the action potential sodium channel. Proc Natl Acad Sci U S A (1986) 4.61
First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: safety and host response. J Infect Dis (1998) 3.60
Gene inoculation generates immune responses against human immunodeficiency virus type 1. Proc Natl Acad Sci U S A (1993) 3.49
The gating mechanism of the large mechanosensitive channel MscL. Nature (2001) 3.43
Epitope mapping of CCR5 reveals multiple conformational states and distinct but overlapping structures involved in chemokine and coreceptor function. J Biol Chem (1999) 3.35
A point mutation in the neu oncogene mimics ligand induction of receptor aggregation. Nature (1989) 3.27
Intestinal M cells: a pathway for entry of reovirus into the host. Science (1981) 3.23
Antigen- and receptor-driven regulatory mechanisms. IV. Idiotype-bearing I-J+ suppressor T cell factors induce second-order suppressor T cells which express anti-idiotypic receptors. J Exp Med (1980) 3.21
Induction of cell differentiation by human immunodeficiency virus 1 vpr. Cell (1993) 2.90
Membrane topology and multimeric structure of a mechanosensitive channel protein of Escherichia coli. EMBO J (1996) 2.81
Atomic scale structure and functional models of voltage-gated potassium channels. Biophys J (1992) 2.80
Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies. Cell (1985) 2.75
Infectious rotavirus enters cells by direct cell membrane penetration, not by endocytosis. J Virol (1988) 2.72
Intermolecular association of the p185neu protein and EGF receptor modulates EGF receptor function. Cell (1990) 2.58
Structural models of the MscL gating mechanism. Biophys J (2001) 2.58
HIV-1 Vpr suppresses immune activation and apoptosis through regulation of nuclear factor kappa B. Nat Med (1997) 2.56
A structural model of the acetylcholine receptor channel based on partition energy and helix packing calculations. Biophys J (1984) 2.53
Mechanisms of regulation of cell-mediated immunity. II. Induction and suppression of delayed-type hypersensitivity to azobenzenearsonate-coupled syngeneic cells. J Immunol (1978) 2.52
Regualtion of the immune response to tumor antigens. I. Immunosuppressor cells in tumor-bearing hosts. J Immunol (1976) 2.42
Hapten-specific T-cell responses to 4-hydroxy-3-nitrophenyl acetyl. II. Demonstration of idiotypic determinants on suppressor T cells. J Exp Med (1979) 2.40
Molecular basis of reovirus virulence. Role of the M2 gene. J Exp Med (1980) 2.32
Synergistic interaction of p185c-neu and the EGF receptor leads to transformation of rodent fibroblasts. Cell (1989) 2.30
Bound water molecules and conformational stabilization help mediate an antigen-antibody association. Proc Natl Acad Sci U S A (1994) 2.18
Molecular pathogenesis of oral squamous cell carcinoma: implications for therapy. J Dent Res (2008) 2.18
Hapten-specific T-cell responses to 4-hydroxy-3-nitrophenyl acetyl. I. Genetic control of delayed-type hypersensitivity by VH and I-A-region genes. J Exp Med (1979) 2.14
Protection of chimpanzees from high-dose heterologous HIV-1 challenge by DNA vaccination. Nat Med (1997) 2.12
The I-J subregion codes for determinats on suppressor factor(s) which limit the contact sensitivity response to picryl chloride. J Exp Med (1977) 2.07
Serum Vpr regulates productive infection and latency of human immunodeficiency virus type 1. Proc Natl Acad Sci U S A (1994) 2.00
Mechanisms of regulation of cell-mediated immunity. III. The characterization of azobenzenearsonate-specific suppressor T-cell-derived-suppressor factors. J Exp Med (1979) 1.99
Reduction of syngeneic tumor growth by an anti-I-J-alloantiserum. Proc Natl Acad Sci U S A (1977) 1.93
Amino acid side-chain partition energies and distribution of residues in soluble proteins. Biophys J (1985) 1.92
Monoclonal antibodies identify a cell-surface antigen associated with an activated cellular oncogene. Nature (1985) 1.88
CD8 positive T cells influence antigen-specific immune responses through the expression of chemokines. J Clin Invest (1998) 1.87
Regulation of the immune response to tumor antigens. II. The nature of immunosuppressor cells in tumor-bearing hosts. J Immunol (1976) 1.83
Prevention of breast tumour development in vivo by downregulation of the p185neu receptor. Nat Med (1995) 1.81
Idiotypic mimicry of biological receptors. Annu Rev Immunol (1986) 1.78
Regulation of the immune response to tumor antigens. III. Characterization of thymic suppressor factor(s) produced by tumor-bearing hosts. J Immunol (1977) 1.76
Effect of passive smoking on birth-weight. Lancet (1986) 1.75
p185neu expression in human lung adenocarcinomas predicts shortened survival. Cancer Res (1990) 1.75
Genetic and molecular mechanisms of viral pathogenesis: implications for prevention and treatment. Nature (1982) 1.75
Structure-function relationships in the activation of platelet thrombin receptors by receptor-derived peptides. J Biol Chem (1992) 1.74
Extracellular Vpr protein increases cellular permissiveness to human immunodeficiency virus replication and reactivates virus from latency. J Virol (1995) 1.74
Impairment of antigen-presenting cell function by ultraviolet radiation. Proc Natl Acad Sci U S A (1979) 1.73
Molecular basis of reovirus neurovirulence: role of the M2 gene in avirulence. Proc Natl Acad Sci U S A (1982) 1.71
TrkB induces EMT and has a key role in invasion of head and neck squamous cell carcinoma. Oncogene (2010) 1.70
Isolation and biochemical characterization of the mammalian reovirus type 3 cell-surface receptor. Proc Natl Acad Sci U S A (1985) 1.70
Evidence that TNF-TNFR1-TRADD-TRAF2-RIP-TAK1-IKK pathway mediates constitutive NF-kappaB activation and proliferation in human head and neck squamous cell carcinoma. Oncogene (2006) 1.68
Differential expression of MMAC/PTEN in glioblastoma multiforme: relationship to localization and prognosis. Cancer Res (1999) 1.66
Differential effects of Bcl-2 on T and B cells in transgenic mice. Proc Natl Acad Sci U S A (1992) 1.65
Nuclear import, virion incorporation, and cell cycle arrest/differentiation are mediated by distinct functional domains of human immunodeficiency virus type 1 Vpr. J Virol (1997) 1.65
Identification of a hemagglutinin-specific idiotype associated with reovirus recognition shared by lymphoid and neural cells. J Exp Med (1982) 1.64
Structural models of the KtrB, TrkH, and Trk1,2 symporters based on the structure of the KcsA K(+) channel. Biophys J (1999) 1.64
Inhibition of thymocyte apoptosis and negative antigenic selection in bcl-2 transgenic mice. Proc Natl Acad Sci U S A (1992) 1.63
Evolutionary relationship between K(+) channels and symporters. Biophys J (1999) 1.63
Antigen- and receptor-driven regulatory mechanisms. I. Induction of suppressor T cells with anti-idiotypic antibodies. J Exp Med (1979) 1.62
Induction of potent Th1-type immune responses from a novel DNA vaccine for West Nile virus New York isolate (WNV-NY1999). J Infect Dis (2001) 1.61
Peptide mimicry of carbohydrate epitopes on human immunodeficiency virus. Nat Biotechnol (1997) 1.61
DNA vaccination: antigen presentation and the induction of immunity. J Leukoc Biol (2000) 1.60
Reovirus serotype 1 intestinal infection: a novel replicative cycle with ileal disease. J Virol (1985) 1.59
Vaccination of seronegative volunteers with a human immunodeficiency virus type 1 env/rev DNA vaccine induces antigen-specific proliferation and lymphocyte production of beta-chemokines. J Infect Dis (2000) 1.59
Inhibition of tumor growth by a monoclonal antibody reactive with an oncogene-encoded tumor antigen. Proc Natl Acad Sci U S A (1986) 1.56
Molecular detection of bacterial DNA in venereal-associated arthritis. Arthritis Rheum (1996) 1.55
In vivo engineering of a cellular immune response by coadministration of IL-12 expression vector with a DNA immunogen. J Immunol (1997) 1.53
The glucocorticoid receptor type II complex is a target of the HIV-1 vpr gene product. Proc Natl Acad Sci U S A (1995) 1.53
Stage- and tissue-specific expression of the neu oncogene in rat development. Proc Natl Acad Sci U S A (1987) 1.52
The neu-oncogene: signal transduction pathways, transformation mechanisms and evolving therapies. Oncogene (1994) 1.51
IL-12 gene as a DNA vaccine adjuvant in a herpes mouse model: IL-12 enhances Th1-type CD4+ T cell-mediated protective immunity against herpes simplex virus-2 challenge. J Immunol (1999) 1.48
Syngeneic monoclonal antiidiotype can induce cellular immunity to reovirus. J Exp Med (1984) 1.48
Antigen- and receptor-driven regulatory mechanisms. III. Induction of delayed type hypersensitivity to azobenzenearsonate with anti-cross-reactive idiotypic antibodies. J Exp Med (1980) 1.48
Gut mucosal immunization with reovirus serotype 1/L stimulates virus-specific cytotoxic T cell precursors as well as IgA memory cells in Peyer's patches. J Exp Med (1987) 1.48
Structural models of the transmembrane region of voltage-gated and other K+ channels in open, closed, and inactivated conformations. J Struct Biol (1998) 1.47
Synthetic CD4 exocyclics inhibit binding of human immunodeficiency virus type 1 envelope to CD4 and virus replication in T lymphocytes. Nat Biotechnol (1997) 1.47
Cell receptors for the mammalian reovirus. I. Syngeneic monoclonal anti-idiotypic antibody identifies a cell surface receptor for reovirus. J Immunol (1983) 1.46
Theoretical models of the ion channel structure of amyloid beta-protein. Biophys J (1994) 1.44
Nucleic acid sequence of an internal image-bearing monoclonal anti-idiotype and its comparison to the sequence of the external antigen. Proc Natl Acad Sci U S A (1986) 1.43
Monoclonal antibodies reactive with distinct domains of the neu oncogene-encoded p185 molecule exert synergistic anti-tumor effects in vivo. Oncogene (1988) 1.43
Magainin 2, a natural antibiotic from frog skin, forms ion channels in lipid bilayer membranes. Eur J Pharmacol (1992) 1.42
Antigen- and receptor-driven regulatory mechanisms. II. Induction of suppressor T cells with idiotype-coupled syngeneic spleen cells. J Exp Med (1979) 1.42
Educational intervention by computer in childhood asthma: a randomized clinical trial testing the use of a new teaching intervention in childhood asthma. Pediatrics (1986) 1.42
Control of MHC restriction by TCR Valpha CDR1 and CDR2. Science (1996) 1.40
Regulation of the immune response to tumor antigen. IV. Tumor antigen-specific suppressor factor(s) bear I-J determinants and induce suppressor T cells in vivo. J Immunol (1978) 1.40
An evaluation of an innovative multimedia educational software program for asthma management: report of a randomized, controlled trial. Pediatrics (2000) 1.40
The tyrosine phosphatase SHP-2 is required for mediating phosphatidylinositol 3-kinase/Akt activation by growth factors. Oncogene (2001) 1.39
Strong conformational propensities enhance T cell antigenicity. J Immunol (1987) 1.39
YAP modifies cancer cell sensitivity to EGFR and survivin inhibitors and is negatively regulated by the non-receptor type protein tyrosine phosphatase 14. Oncogene (2012) 1.36
Identification and characterization of a varicella-zoster virus DNA-binding protein by using antisera directed against a predicted synthetic oligopeptide. J Virol (1988) 1.35
Idiotype-specific T cell immunity. I. Generation of effector and suppressor T lymphocytes reactive with myeloma idiotypic determinants. J Immunol (1980) 1.35
Prototype development and preclinical immunogenicity analysis of a novel minimally invasive electroporation device. Gene Ther (2010) 1.35
Structural similarities between the mammalian beta-adrenergic and reovirus type 3 receptors. Proc Natl Acad Sci U S A (1985) 1.34
Linkage of tyrosine kinase activity with transforming ability of the p185neu oncoprotein. Oncogene (1989) 1.34
HER2/neu: mechanisms of dimerization/oligomerization. Oncogene (2000) 1.33